Stay updated on STRO-002 Combo with Bevacizumab in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the STRO-002 Combo with Bevacizumab in Ovarian Cancer Clinical Trial page.

Latest updates to the STRO-002 Combo with Bevacizumab in Ovarian Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check20 days agoNo Change Detected
- Check35 days agoChange DetectedFallopian tube cancer was added to the conditions list. The page revision was updated from v3.4.1 to v3.4.2.SummaryDifference0.1%

- Check42 days agoChange DetectedAdded primary peritoneal carcinoma to the conditions and included the Genetic and Rare Diseases Information Center under resources. Revision updated from v3.4.0 to v3.4.1.SummaryDifference0.2%

- Check43 days agoChange DetectedRevision: v3.4.1 is displayed in place of v3.4.0, a minor version label update that does not affect study content or available actions for users.SummaryDifference0.1%

- Check50 days agoChange DetectedAdded a Show glossary option and updated the QC status line to 'Last Update Submitted that Met QC Criteria.' Minor capitalization changes for 'No FEAR Act Data' and a site revision label 'Revision: v3.4.0' were also applied.SummaryDifference0.2%

- Check57 days agoChange DetectedThe page now displays a 'Last Update Posted' timestamp field, and the previous 'Last Update Posted (Estimated)' label has been removed. This is a UI/metadata update rather than a change to study content or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to STRO-002 Combo with Bevacizumab in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the STRO-002 Combo with Bevacizumab in Ovarian Cancer Clinical Trial page.